

Maralixibat: Adis Evaluation

Key Points

- A small-molecule ileal bile acid transporter (IBAT) inhibitor is being developed by Mirum Pharmaceuticals for the treatment of cholestatic liver diseases
- Received its first approval on 29 September 2021 in the USA
- Approved for use in the treatment of cholestatic pruritus in patients 1 year of age and older with Alagille syndrome (ALGS)

Summary

Maralixibat (Livmarli™) is an orally-administered, small-molecule ileal bile acid transporter (IBAT) inhibitor being developed by Mirum Pharmaceuticals for the treatment of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.

Maralixibat received its first approval on 29 September 2021, in the USA, for use in the treatment of cholestatic pruritus in patients with ALGS 1 year of age and older.

Maralixibat is also under regulatory review for ALGS in Europe, and clinical development for cholestatic liver disorders including ALGS in patients under 1 year of age, PFIC and biliary atresia is continuing in several other countries.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2021.